Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
暂无分享,去创建一个
J. Tabernero | A. Abad | F. Rivera | E. Díaz-Rubio | M. Benavides | E. Aranda | J. Sastre | M. Vidaurreta | E. Marcuello | A. Arriví | A. Gómez-España | M. Maestro | E. González | M. Valladares | M. Gallén | C. Fernández‐Martos | B. Massutí | C. Fernández-Martos
[1] J. Tabernero,et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. , 2012, The oncologist.
[2] I. Nagtegaal,et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Michael Morse,et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Sanz-Casla,et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] Brigitte Rack,et al. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.
[6] Jonathan W. Uhr,et al. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.
[7] A. Stopeck,et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases , 2004 .
[8] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.